Michael Kavanaugh - CytomX Therapeutics Executive

CTMX Stock  USD 2.19  0.08  3.79%   

Executive

Mr. W. Michael Kavanaugh, M.D. serves as a Chief Scientific Officer and Head Research and NonClinical Development of the company. Dr. Kavanaugh joined us as chief scientific officer and head of research and nonclinical development in January 2015. Prior to joining us, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics, Inc. From February 2009 to December 2014, Dr. Kavanaugh held multiple positions in research and development at Five Prime Therapeutics, Inc. and led the growth of its therapeutic pipeline. Prior to that, Dr. Kavanaugh served as vice president of Novartis Vaccines Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis as part of its acquisition of the Chiron Corporation in 2006, where he held positions as vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his M.D. from Vanderbilt University and his B.S. in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at University of California, San Francisco, and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of Medicine at University of California, San Francisco. since 2015.
Age 61
Tenure 9 years
Address 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone650 515 3185
Webhttps://www.cytomx.com

CytomX Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.0175) % which means that it has lost $0.0175 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.14) in 2024. At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 5.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 19.8 M in 2024.
The company currently holds 13.97 M in liabilities with Debt to Equity (D/E) ratio of 0.67, which is about average as compared to similar companies. CytomX Therapeutics has a current ratio of 2.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist CytomX Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, CytomX Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CytomX Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CytomX to invest in growth at high rates of return. When we think about CytomX Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Maria MartinezJJill Inc
56
Eva SerranoPVH Corp
51
Mame AnnanBrownKontoor Brands
N/A
Ellen ConstantinidesPVH Corp
N/A
Sung IpHK Electric Investments
58
Neala ShepherdDuluth Holdings
46
Wai NgHK Electric Investments
47
Yuk WongHK Electric Investments
59
Marianne SchlechtDuluth Holdings
72
Tak YeeHK Electric Investments
62
Amber McCannPVH Corp
N/A
Sanjeev MohantyLevi Strauss Co
N/A
Karla FriedersSteven Madden
47
Ezio GarciamendezKontoor Brands
N/A
Albert SuteraDuluth Holdings
58
Elliot StaplesJJill Inc
N/A
Dawn VitaleLevi Strauss Co
N/A
Joseph TeklitsJJill Inc
N/A
Awadhesh SinhaSteven Madden
78
Karyn HillmanLevi Strauss Co
56
Todd JacobsBlack Hills
55
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Cytomx Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 174 people. CytomX Therapeutics (CTMX) is traded on NASDAQ Exchange in USA. It is located in 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 120 people. CytomX Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

CytomX Therapeutics Leadership Team

Elected by the shareholders, the CytomX Therapeutics' board of directors comprises two types of representatives: CytomX Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CytomX. The board's role is to monitor CytomX Therapeutics' management team and ensure that shareholders' interests are well served. CytomX Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CytomX Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
MBA BS, Head VP
Matthew Young, Independent Director
Hoyoung Huh, Chairman of the Board
Charles Fuchs, Director
JD Rowland, General VP
Danielle OlanderMoghadassian, Senior Officer
YuWaye MD, Senior Officer
Leslie Robbins, Senior Vice President - Intellectual Property
Sean McCarthy, President CEO, Director
Sean DPHIL, Chairman CEO
Christopher Ogden, Principal Accounting
Marcia Belvin, Senior Officer
Chau MBA, Vice Communications
Timothy Shannon, Independent Director
John Scarlett, Director
Debanjan Ray, CFO, Principal Financial and Accounting Officer
Jamie Moore, VP Manufacturing
Lloyd Rowland, Senior Vice President Chief Compliance Officer, General Counsel, Secretary
Nick Galli, Senior Vice President Chief Business Officer
Marion McCourt, Director
James Meyers, Independent Director
Rachel Humphrey, Chief Medical Officer
Elaine Jones, Independent Director
Cynthia Ladd, Senior Vice President General Counsel
Michael Kavanaugh, Chief Scientific Officer and Head - Research and Non-Clinical Development
Frederick Gluck, Co-Founder and Director
Christopher Keenan, Vice President Investor Relations and Corporate Communications Vice President Investor Relations and Corporate Communications
Robert Goeltz, CFO
Neil Exter, Independent Director
Hoyoung MD, Special Officer
Dawn Benson, Senior Manufacturing
DPHIL DPhil, Chairman CEO

CytomX Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CytomX Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with CytomX Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CytomX Stock

  0.67MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr
  0.61EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against CytomX Stock

  0.85KA Kineta Inc Report 29th of March 2024 PairCorr
  0.81TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.61MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.57VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.52MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CytomX Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytomX Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomx Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomx Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for CytomX Stock analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Revenue Per Share
1.371
Quarterly Revenue Growth
0.322
Return On Assets
(0.02)
Return On Equity
(54.75)
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.